Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Shield Therapeutics ( (GB:STX) ) has issued an announcement.
Shield Therapeutics announced that its Chief Executive Officer, Anders Lundstrom, has acquired 575,000 ordinary shares of the company, enhancing his investment in Shield Therapeutics. This move reflects confidence in the company’s strategic positioning, particularly in the iron deficiency treatment market, where ACCRUFeR®/FeRACCRU® is expected to meet significant unmet needs. With a strong patent position and expanding international presence, Shield Therapeutics continues to strengthen its market position.
More about Shield Therapeutics
Shield Therapeutics plc is a commercial stage specialty pharmaceutical company focused on addressing iron deficiency with its innovative product, ACCRUFeR®/FeRACCRU®. The company has successfully launched this FDA-approved oral iron therapy in the U.S. in collaboration with Viatris Inc. and has licensed commercialization rights to several international partners, including Norgine B.V. for the UK and European Union.
YTD Price Performance: 42.59%
Average Trading Volume: 2,978,536
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £40.11M
For detailed information about STX stock, go to TipRanks’ Stock Analysis page.
